Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients

Journal of Immunology

Volumn 181, Issue 1, 2008, Pages 431-439

  Wang, Xiao Fei ^a   Kerzerho, Jerome ^a   Adotevi, Olivier ^b   Nuyttens, Hélène ^a   Badoual, Cecile ^b   Munier, Gaetan ^a   Oudard, Stéphane ^c   Tu, Shuiping ^d   Tartour, Eric ^a   Maillère, Bernard ^a,e  

^a CEA SACLAY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DP4 ANTIGEN; HLA DR ANTIGEN; RECOMBINANT PROTEIN; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; HLA DP4; HLA-DP4; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; CELL DIFFERENTIATION; CELL LINE; HEALTH; IMMUNOLOGY; NEOPLASM;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE; DENDRITIC CELLS; HEALTH; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DP ANTIGENS; HLA-DR ANTIGENS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 47949109602     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.1.431     Document Type: Article

References (47)

1. Li, F. 2003. Survivin sludy: what is the next wave? J. Cell. Physiol. 197: 8-29.
2. Ambrosini, G., C. Adida, and D. C. Altieri. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3: 917-921.
3. Li, F., G. Ambrosini, E. Y. Chu, J. Plescia, S. Tognin, P. C. Marchisio, and D. C. Altieri. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584.
4. Adida, C., C. Haioun, P. Gaulard, E. Lepage, P. Morel, J. Briere, H. Dombret, F. Reyes, J. Diebold, C. Gisselbrecht, et al. 2000. Prognostic significance of survivin expression in diffuse large B-cell Iymphomas. Blood 96: 1921-1925.
5. Olie, R. A., A. P. Simoes-Wust, B. Baumann, S. H. Leech, D. Fabbro, R. A. Stahel, and U. Zangemeister-Wittke. 2000. A novel antisense oligonucle-otide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60: 2805-2809.
6. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60: 4845-4849.
7. Andersen, M. H., L. O. Pedersen, J. C. Becker, and P. T. Straten. 2001. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61: 869-872.
8. Hirohashi, Y., T. Torigoe, A. Maeda, Y. Nabeta, K. Kamiguchi, T. Sato, J. Yoda, H. Ikeda, K. Hirata, N. Yamanaka, and N. Sato. 2002. An HLA-A24-restricted cytbtoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin. Cancer Res. 8: 1731-1739.
9. Reker, S., J. C. Becker, I. M. Svane, E. Ralfkiaer, P. T. Straten, and M. H. Andersen. 2004. HLA-B35-restricted immune responses against survivin in cancer patients. Int. J. Cancer 108: 937-941.
10. + T cells in colorectal cancer patients. Cancer Res. 63: 4507-4515.
11. Schmidt, S. M., K. Schag, M. R. Muller, M. M. Weck, S. Appel, L. Kanz, F. Grunebach, and P. Brossart. 2003. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102: 571-576.
12. Fuessel, S., A. Meye, M. Schmitz, S. Zastrow, C. Linne, K. Richter, B. Lobel, O. W. Hakenberg, K. Hoelig, E. P. Rieber, and M. P. Wirth. 2006. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 66: 811-821.
13. Nagaraj, S., V. Pisarev, L. Kinarsky, S. Sherman, C. Muro-Cacho, D. C. Altieri, and D. I. Gabrilovich. 2007. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J. Immunother. 30: 169-179.
14. Otto, K., M. H. Andersen, A. Eggert, P. Keikavoussi, L. O. Pedersen, J. C. Rath, M. Bock, E. B. Brocker, P. T. Straten, E. Kampgen, and J. C. Becker. 2005. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 23: 884-889.
15. Wobser, M., P. Keikavoussi, V. Kunzmann, M. Weininger, M. H. Andersen, and J. C. Becker. 2006. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 55: 1294-1298.
16. Tocs, R. E., F. Ossendorp, R. Offringa, and C. J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189: 753-756.
17. Piesche, M., Y. Hildebrandt, F. Zettl, B. Chapuy, M. Schmitz, G. Wulf, L. Trumper, and R. Schroers. 2007. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum. Immunol. 68: 572-576.
18. Megliorino, R., F. D. Shi, X. X. Peng, X. Wang, E. K. Chan, E. M. Tan, and J. Y. Zhang. 2005. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect. Prev. 29: 241-248.
19. Rohayem, J., P. Diestelkoetter, B. Weigle, A. Oehmichen, M. Schmitz, J. Mehlhorn, K. Conrad, and E. P. Rieber. 2000. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 60: 1815-1817.
20. + T cell immunity to mouse survivin. J. Immunol. 177: 8410-8421.
21. Tu, S. P., X. H. Jiang, M. C. Lin, J. T. Cui, Y. Yang, C. T. Lum, B. Zou, Y. B. Zhu, S. H. Jiang, W. M. Wong, et al. 2003. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 63: 7724-7732.
22. Texier, C., S. Pouvelle, M. Busson, M. Herve, D. Charron, A. Menez, and B. Maillere. 2000. HLA-DR restricted peptide candidates for bee venom immu-notherapy. J. Immunol. 164: 3177-3184.
23. Texier, C., S. Pouvelle-Moratille, M. Busson, D. Charron, A. Menez, and B. Maillere. 2001. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31: 1837-1846.
24. Castelli, F. A., C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Segard, J. G. Guillet, A. Menez, B. Georges, and B. Maillere. 2002. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of pep-tide-binding specificity. J. Immunol. 169: 6928-6934.
25. + T cell epitopes of HCV NS3 and core proteins. Eur. J. Immunol. 37: 1513-1523.
26. + T cells. Cancer Res. 62: 213-218.
27. + T lymphocytes. Hum. Immunol. 65: 1307-1318.
28. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.
29. Sturniolo, T., E. Bono, J. Ding, L. Raddrizzani, O. Tuereci, U. Sahin, M. Braxenthaler, F. Gallazzi, M. P. Protti, F. Sinigaglia, and J. Hammer. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 17: 555-561.
30. Gammon, G., N. Shastri, J. Cogswell, S. Wilbur, S. Sadegh-Nasseri, U. Krzych, A. Miller, and E. Sercarz. 1987. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol. Rev. 98: 53-73.
31. Assarsson, E., J. Sidney, C. Oseroff, V. Pasquetto, H. H. Bui, N. Frahm, C. Brander, B. Peters, H. Grey, and A. Sette. 2007. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J. Immunol. 178: 7890-7901.
32. + T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 174: 1633-1640.
33. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. USA 100: 8862-8867.
34. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19: 2237-2242.
35. + T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J. Virol. 70: 4787-4790.
36. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71: 6011-6019.
37. + T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27: 203-213.
38. Jing, L., T. M. Chong, B. Byrd, C. L. McClurkan, J. Huang, B. T. Story, K. M. Dunkley, L. Aldaz-Carroll, R. J. Eisenbcrg, G. H. Cohen, et al. 2007. Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J. Immunol. 178: 6374-6386.
39. + T cell epitopes restricted to HLA-DP4, the most prevalent HLA class II molecule. J. Immunol. 176: 5401-5408.
40. Wang, X. F., W. M. Cohen, F. A. Castelli, C. Almunia, B. Lethe, S. Pouvelle-Moratille, G. Munier, D. Charron, A. Menez, H. M. Zarour, et al. 2007. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol. Immunother. 56: 807-818.
41. + T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62: 3630-3635.
42. Raddrizzani, L., T. Stumiolo, J. Guenot, E. Bono, F. Gallazzi, Z. A. Nagy, F. Sinigaglia, and J. Hammer. 1997. Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. J. Immunol. 159:703-711.
43. Sidney, J., C. Oseroff, S. Southwood, M. Wall, G. Ishioka, F. Koning, and A. Sette. 1992. DRBl*0301 molecules recognize a structural motif distinct from the one recognized by most DR beta 1 alleles. J. Immunol. 149: 2634-2640.
44. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
45. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185: 833-841.
46. Andersen, M. H., L. O. Pedersen, B. Capeller, E. B. Brocker, J. C. Becker, and P. thor Stratea 2001. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61: 5964-5968.
47. + T cell responses against TRAG-3 in patients with melanoma and breast cancers. J. Immunol. 177: 2717-2727.